Despite the major role of MAPK pathway in colorectal cancer (CRC) and papillary thyroid cancer (PTC), there are few reports about the prevalence of MAP2K1 mutations in these tumor sites (17, 20–22). This evidence concerns the gene MAP2K1 and thyroid gland papillary carcinoma.